Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

s or labeling in any market, or at any particular time. Nor can there be any guarantee that everolimus will achieve any particular levels of revenue in the future. In particular, management's expectations regarding everolimus could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations ac
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Medina Medical announced today that Mr. ... the Board of Directors on August 18, 2014. Mr. ... commercialization experience, including over a decade of direct experience ... a Partner of the medical device incubator The Foundry, ... Foundry start-ups. Mr. Engelson previously served as the Chief ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , , LAKE FOREST, Ill. ... leading developer and manufacturer of injectable pharmaceuticals announced today ... of Corvert ® from Pfizer Inc. , (Logo: ... Injection further demonstrates Bioniche Pharma,s continued growth and dedication ...
... CHARLOTTESVILLE, Virginia , January ... and Drug Administration (FDA) has licensed its,technology platform to help ... harmful side effects. , The FDA,s ... Research (CDER), will test the use of Biovista,s Adverse Event,Analysis ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative 2
(Date:8/30/2014)... "My wife suffered neck, back and spine injuries ... of two inventors from Bethel, Alaska. "The whiplash contributed ... area. She tried other pillows to little avail. The ... comfort and providing extra sleep." , They created a ... head, neck and back comfortably. This enables the user ...
(Date:8/30/2014)... 30, 2014 "My niece developed a ... at any moment, her fever might get worse," said ... me well aware of how she was doing, I ... ALARM to continuously monitor a child's temperature. The unit ... This ensures that prompt medical care can be given, ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 ... transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against ... to sever four cases selected for one of ... issued on August 18, 2014, U.S. District Judge ... West Virginia disagrees with Boston Scientific’s contention that ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... CORONA, Calif., July 25 Watson,Pharmaceuticals, Inc. ... announced today that its subsidiary has commenced commercial,shipment ... the 40mg,strength from its Davie, Florida manufacturing facility. ... of marketing exclusivity for being the,first to file ...
... to benefit ALS Therapy Alliance to be presented at Fenway Park ... ... CVS/pharmacy announced today,that this year it has raised a record-breaking $4.4 ... research. This is,the seventh year of the annual fundraising effort which, to ...
... of New York will present an educational meeting regarding age-related macular ... the Farmingdale Public Library at 116 Merritts Road, Farmingdale, NY 11735, ... and refreshments will be provided. The phone number for pre-registration is ... ...
... at Wake Forest University Baptist Medical Center have disproved ... slows or stunts the immune system,s ability to restore ... of drugs known as the "cocktail." , Hepatitis ... leading to rapid liver damage, according to the Centers ...
... Experience it ... Are you an e-patient?,Studies show that 80 percent ... to Web 2.0, e-patients now have even more ways,to ... learn about,advanced medical technologies. Go to http://SutterHealth.org/annualreport ,and ...
... 24 AMICAS, Inc. (Nasdaq: AMCS ),a leader in ... will report the company,s financial results,for the second quarter ending ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... Tuesday, August 5, 2008 -- Call begins ...
Cached Medicine News:Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:AMICAS Schedules Second Quarter Earnings Call 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: